[
  {
    "sentence": "Notably, TGFB1 turned out to be an adverse prognosticator of OS for all three cancers (Fig. 3A–C).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Notably, TGFB1 turned out to be an adverse prognosticator of OS for all three cancers (Fig. 3A–C).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In DLBCL and MM, a strong positive association was observed between TGFB1 expression and pro-tumor cytokines; whereas in MDS and CML, TGFB1 expression was positively correlated with tumor-suppressive components like NK and T cells and was negatively correlated with epithelial-to-mesenchymal transition (EMT) and tumor proliferation rate (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "TGFB1 expression was positively correlated with immune score in most blood cancer types, the most prominent ones being MDS and CML (Fig. 4B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel B",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "This was true when immune score was calculated by xCELL algorism (Fig. 4C).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel C",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "TGFB1 expression was positively correlated with the stromal score in AML, classical Hodgkin lymphoma (CHL), CLL, CML, DLBCL, mantle cell lymphoma (MCL), MDS, MM, pre-B ALL, and T-ALL (Fig. 4D).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel D",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The results again revealed strongest correlation between TGFB1 expression and cytolytic score in CML and MDS (Fig. 4E).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel E",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Interestingly, TGFB1 were positively correlated with the level of CD8 + T cells and NK cells but negatively correlated with that of CD4 + T cell (Fig. 4F).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel F",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "In line with previous results, TGFB1 is highly expressed in monocytes/macrophages, NK and CD8 + T cells in these cancers (Fig. 4G).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel G",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Moreover, we also found that TGFB1 was positively associated with the p53 pathway, KRAS signaling-up, and apical junction but was negatively associated with MYC targets, E2F targets, and G2M checkpoint in most cancers (Fig. 5A).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "We also identified pathways negatively associated with TGFB1: KRAS signaling-down, apical surface, bile-acid metabolism, and WNT-BETA-CATENIN signaling (Fig. 5B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Moreover, we also found that TGFB1 was positively associated with the p53 pathway, KRAS signaling-up, and apical junction but was negatively associated with MYC targets, E2F targets, and G2M checkpoint in most cancers (Fig. 5A).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "We also identified pathways negatively associated with TGFB1: KRAS signaling-down, apical surface, bile-acid metabolism, and WNT-BETA-CATENIN signaling (Fig. 5B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "For French-American-British (FAB) classification of AML, more M4 and M5 subtypes and less M2 and M3 subtypes were presented in patients with high TGFB1 expression (Fig. 8A).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "No significant associations were found between TGFB1 expression and other clinical parameters, although patients with high TGFB1 expression tended to have higher white blood cell (WBC) counts than those with low TGFB1 expression (Fig. 8A).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "As shown in Fig. 8B, patients with high TGFB1 expression more frequently harbored NRAS and DNMT3A mutations and less frequently harbored WT1 mutation (Fig. 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "For French-American-British (FAB) classification of AML, more M4 and M5 subtypes and less M2 and M3 subtypes were presented in patients with high TGFB1 expression (Fig. 8A).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "No significant associations were found between TGFB1 expression and other clinical parameters, although patients with high TGFB1 expression tended to have higher white blood cell (WBC) counts than those with low TGFB1 expression (Fig. 8A).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "As shown in Fig. 8B, patients with high TGFB1 expression more frequently harbored NRAS and DNMT3A mutations and less frequently harbored WT1 mutation (Fig. 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "We also noticed that TGFB1 expression was positively associated with CAF signature in DLBCL (Fig. 4A).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  }
]